Winston Dunn, M.D.
Dr. Dunn completed his residency training in Internal Medicine at The Mayo Clinic, Rochester. He then completed his Gastroenterology Fellowship from the University of California, San Diego, and subsequently Transplant Hepatology Fellowship at The Mayo Clinic, Rochester as well. Currently, he is an Associate Professor of Medicine in the Department of Gastroenterology at the University of Kansas Health System, Kansas City, KS.
Education and Training
- BS, Univ. of British Columbia
- MD, Finch Univ of Health Sciences
- Residency, Internal Medicine Residency, Mayo Graduate School of Medicine, Rochester, MN
- Clinical Fellowship, Gastroenterology Fellowship, University of California, San Diego, San Diego, CA, CA
- Clinical Fellowship, Transplant Hepatology Fellowship, Mayo Graduate School of Medicine, Rochester, MN
- AASLD, ALD SIG Education Committee, Chair, 2019 - Present
Dr. Dunn has two lines of investigator-initiated researches related to the genetics of fibrosis regression and Linkage to Care in Nonalcoholic Steatohepatitis (NASH). He also has four industry-sponsored trials on the treatment of NASH.
The first research investigator-sponsored research Factors responsible for Liver Recovery after Successful Treatment of Hepatitis C is currently funded by the K23 Mentored Patient-Oriented Research Career Development Award of NIDDK. The overall goal of this study is to identify genetic determinants of recovery from cirrhosis following the successful clearance of HCV infection. This case-control study uses Fibroscan® and ELF to ascertain cirrhosis regression. Dr. Dunn found that differences in population genetics were associated with cirrhosis regression after the clearance of HCV infection. Pathways involved in lipid metabolism and striated-muscle contraction may play a role in determining the risk of cirrhosis regression.
The second research investigator-sponsored research 3 Improving Referral, Diagnosis, and Linkage to Care for Patients with Nonalcoholic Steatohepatitis (NASH) is sponsored by Gilead NASH Models of Care ISR Program. This study will accomplish the three-part objective described in the title through three Specific Aims. The first unmet need that the proposed research seeks to address is to improve appropriate referrals of high-risk patients to a hepatology provider. The first aim is to determine if rates of referral to hepatology can be improved through a medical record (EMR)-based Best Practice Alert (BPA) for an appropriate referral. The second unmet need is to determine how to optimize the use of liver biopsy for the diagnosis of NASH with ≥ F2 fibrosis. The second aim is to quantify how the availability of the enhanced liver fibrosis (ELF) test affects the rate of diagnosis of NASH with ≥ F2 fibrosis in patients referred to hepatology for NAFLD evaluation. The third unmet need is to determine the circumstances for which hepatology referral results in a clinical benefit to the patient. The third aim is to evaluate the impact of the hepatology referral on the 5 outcomes in patients co-managed and not co-managed by hepatology.
In addition, Dr. Dunn is the PI of two NASH clinical trials that are still enrolling at this time. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis. A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH).
Current Research and Grants
- Factors Responsible for Liver Recovery after Successful Treatment of Hepatitis C, NIDDK, PI
- Improving Referral, Diagnosis, and Linkage to Care for Patients with Nonalcoholic Steatohepatitis (NASH)., Gilead NASH Models of Care ISR Program, PI
- AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis, Tobira Therapeutics, PI
- A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation, Madrigal Pharmaceuticals, Inc., PI
- 747-303 Randomized Global Phase 3 Study to Evaluate the Impact on NASH with Fibrosis of Obeticholic Acid Treatment (REGENERATE), Intercept Pharmaceuticals Inc., PI
- A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis(REVERSE Study), Intercept Pharmaceuticals, PI
- Dunn, W, Vittal, A, Zhao, J, He, J, Chakraborty, S, Whitener, M, Fohn, S, Ash, R, Taylor, R., M, Olyaee, M, Olson, J., C, Todd, N, Floyd, B., N, Pandya, P, Laycock, M, Schmitt, T, Weinman, S., A. 2019. PNPLA3 gene predicts clinical recovery after sustained virological response in decompensated hepatitis C cirrhosis.. BMJ open gastroenterology, 6 (1), e000241
- Dunn, W, Chalasani, N. 2019. Advice Regarding Alcohol Use by Individuals With Nonalcoholic Fatty Liver Disease: Primum non nocere.. Hepatology (Baltimore, Md.), 69 (1), 9-11
- Dunn, W, O'Neil, M, Zhao, J, Wu, C., H, Roberts, B, Chakraborty, S, Sherman, C, Weaver, B, Taylor, R, Olson, J, Olyaee, M, Gilroy, R, Schmitt, T, Wan, Y., J, Weinman, S., A. 2014. Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C.. Hepatology (Baltimore, Md.), 59 (2), 453-60
- Weng, G, Dunn, W. 2019. Effect of alcohol consumption on nonalcoholic fatty liver disease.. Translational gastroenterology and hepatology, 4, 70
- Al-Hihi, E, Shankweiler, C, Stricklen, D, Gibson, C, Dunn, W. 2017. Electronic medical record alert improves HCV testing for baby boomers in primary care setting: adults born during 1945-1965.. BMJ open quality, 6 (2), e000084
- Vaa, B., E, Asrani, S., K, Dunn, W, Kamath, P., S, Shah, V., H. 2011. Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis.. Mayo Clinic proceedings, 86 (1), 37-42
- Dunn, W, Jamil, L., H, Brown, L., S, Wiesner, R., H, Kim, W., R, Menon, K., V, Malinchoc, M, Kamath, P., S, Shah, V. 2005. MELD accurately predicts mortality in patients with alcoholic hepatitis.. Hepatology (Baltimore, Md.), 41 (2), 353-8
- Dunn, W, Sanyal, A., J, Brunt, E., M, Unalp-Arida, A, Donohue, M, McCullough, A., J, Schwimmer, J., B. 2012. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD).. Journal of hepatology, 57 (2), 384-91
- Dunn, W, Xu, R, Schwimmer, J., B. 2008. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease.. Hepatology (Baltimore, Md.), 47 (6), 1947-54
- Dunn, W, Angulo, P, Sanderson, S, Jamil, L., H, Stadheim, L, Rosen, C, Malinchoc, M, Kamath, P., S, Shah, V., H. 2006. Utility of a new model to diagnose an alcohol basis for steatohepatitis.. Gastroenterology, 131 (4), 1057-63